Announcements Trials
Browse Landscape

Status

Completed 22Terminated 9Active not recruiting 4Withdrawn 3Unknown 3Recruiting 3No longer available 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

Thoracic 2Plasma cell 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Lymphoma, Large-Cell, Anaplastic 1Granuloma, Plasma Cell 1

Interventions

trametinib 4nilotinib 4elotuzumab 4dabrafenib 4Amifampridine 4regorafenib 3pembrolizumab 3midostaurin 3fludarabine phosphate 3fludarabine 3Nivolumab 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Cyclophosphamide 3Crizotinib 3Bortezomib 3Axitinib 3venetoclax 2veliparib 2tazemetostat 2talimogene laherparepvec 2navitoclax 2gallium 68 PSMA-11 2ceritinib 2carbon-11 acetate 2aldesleukin 2Whole-Body Irradiation 2Trabectedin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
No longer available × ceritinib × Clear all
NCT05100134 2026-04-01

Managed Access Programs for LDK378, Ceritinib

Novartis

No longer available
LymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

NCT01947608 2020-11-03

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Novartis

No longer available
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡